FY2025 · ended Dec 31, 2025 · Revenue $81,000, +5.2% YoY · Filed Mar 18, 2026
Sera Prognostics, Inc. (SERA) files with the SEC under industry code 8071, Services-Medical Laboratories. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $81,000 and a net loss of $31.9 million. Free cash flow was -$26.3 million. As of Sep 30, 2026 it held $72.8 million in cash and investments and $3.3 million in total debt.
Revenue (TTM)
$96,000
+1.1% vs year-ago TTM
Net income (TTM)
$-33.47M
-2.6% vs year-ago TTM
Operating cash flow (TTM)
$-28.50M
-10.6% vs year-ago TTM
Free cash flow (TTM)
$-28.99M
-10.8% vs year-ago TTM
EPS (TTM)
$-0.66
+11.2% vs year-ago TTM
Dividend per share
None
Shares outstanding
—
Net cash
$69.56M
as of Sep 30, 2026
Operating margin
-38755.2%
FY 2026
Company profile
- Industry
- Services-Medical Laboratories (SIC 8071)
- Listed as
- SERA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Salt Lake City, UT
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1534969
- Former names
- SERA PROGNOSTICS, INC. (until Nov 4, 2026)
Other Services-Medical Laboratories companies
- Natera, Inc. NTRA
- Labcorp Holdings Inc. LH
- Quest Diagnostics Inc DGX
- Guardant Health, Inc. GH
- Caris Life Sciences, Inc. CAI
- GRAIL, Inc. GRAL
- RadNet, Inc. RDNT
- BillionToOne, Inc. BLLN
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $81,000 | $77,000 | $306,000 | $268,000 | $82,000 |
| Operating income | -$36.5M | -$36.6M | -$39.8M | -$45.7M | -$35.4M |
| Net income | -$31.9M | -$32.9M | -$36.2M | -$44.2M | -$35.0M |
| Diluted EPS | -$0.67 | -$0.99 | -$1.16 | -$1.43 | -$2.33 |
| Operating cash flow | -$25.6M | -$14.2M | -$27.2M | -$34.6M | -$31.6M |
| Free cash flow | -$26.3M | -$14.2M | -$27.3M | -$35.4M | -$32.9M |
| Total assets | $101.9M | $72.6M | $95.4M | $116.3M | $147.0M |
| Total liabilities | $26.5M | $24.8M | $25.3M | $17.4M | $8.5M |
| Stockholders' equity | $75.4M | $47.8M | $70.2M | $98.9M | $138.6M |
| Cash and investments | $95.8M | $68.2M | $79.9M | $104.0M | $140.0M |
| Total debt | $2.3M | $840,000 | $1.9M | $2.8M | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 4, 2026 | Nov 4, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Aug 19, 2026 | Aug 14, 2026 |
| 10-Q | Quarterly report | Aug 12, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 12, 2026 | Aug 12, 2026 |
| 8-K |
Current report
Officer or director change
|
Jun 30, 2026 | Jun 25, 2026 |
All 660 Sera Prognostics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.